Ken Page

1.8k total citations
22 papers, 767 citations indexed

About

Ken Page is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, Ken Page has authored 22 papers receiving a total of 767 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 4 papers in Oncology and 4 papers in Pharmacology. Recurrent topics in Ken Page's work include Pharmacogenetics and Drug Metabolism (4 papers), Analytical Chemistry and Chromatography (3 papers) and Computational Drug Discovery Methods (3 papers). Ken Page is often cited by papers focused on Pharmacogenetics and Drug Metabolism (4 papers), Analytical Chemistry and Chromatography (3 papers) and Computational Drug Discovery Methods (3 papers). Ken Page collaborates with scholars based in United Kingdom, United States and Sweden. Ken Page's co-authors include Yan Li, Lars Weidolf, Hugues Dolgos, Emre M. Isin, J. Gerry Kenna, Richard Weaver, Richard A. Thompson, Ian D. Wilson, Brian Middleton and Barbara Hanney and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and Tourism Management.

In The Last Decade

Ken Page

21 papers receiving 736 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ken Page United Kingdom 13 290 243 192 188 107 22 767
Raju Mohan United States 19 647 2.2× 579 2.4× 61 0.3× 219 1.2× 73 0.7× 35 1.3k
Robert B. McFadyen United States 13 279 1.0× 148 0.6× 31 0.2× 227 1.2× 68 0.6× 17 544
Philip Lienau Germany 21 766 2.6× 433 1.8× 79 0.4× 468 2.5× 111 1.0× 37 1.4k
Ted W. Johnson United States 18 790 2.7× 395 1.6× 82 0.4× 156 0.8× 214 2.0× 28 1.6k
Xiaoke Gu China 14 285 1.0× 185 0.8× 43 0.2× 146 0.8× 23 0.2× 34 544
Klaus Pors United Kingdom 20 563 1.9× 250 1.0× 171 0.9× 264 1.4× 38 0.4× 61 1.0k
Yasuhisa Kurogi Japan 15 483 1.7× 359 1.5× 64 0.3× 165 0.9× 277 2.6× 21 982
Karen A. Rossi United States 19 363 1.3× 515 2.1× 31 0.2× 100 0.5× 129 1.2× 45 1.3k
John J. Piwinski United States 21 538 1.9× 565 2.3× 37 0.2× 90 0.5× 83 0.8× 49 1.1k

Countries citing papers authored by Ken Page

Since Specialization
Citations

This map shows the geographic impact of Ken Page's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Page with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Page more than expected).

Fields of papers citing papers by Ken Page

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken Page. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Page. The network helps show where Ken Page may publish in the future.

Co-authorship network of co-authors of Ken Page

This figure shows the co-authorship network connecting the top 25 collaborators of Ken Page. A scholar is included among the top collaborators of Ken Page based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken Page. Ken Page is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Barlaam, Bernard, Sabina Cosulich, Martina Fitzek, et al.. (2017). Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors. Bioorganic & Medicinal Chemistry Letters. 27(13). 3030–3035. 5 indexed citations
2.
Winiwarter, Susanne, et al.. (2015). Time dependent analysis of assay comparability: a novel approach to understand intra- and inter-site variability over time. Journal of Computer-Aided Molecular Design. 29(9). 795–807. 15 indexed citations
3.
Barlaam, Bernard, Sabina Cosulich, Martina Fitzek, et al.. (2015). Design of selective PI3Kα inhibitors starting from a promiscuous pan kinase scaffold. Bioorganic & Medicinal Chemistry Letters. 25(13). 2679–2685. 7 indexed citations
4.
Page, Ken. (2015). Validation of Early Human Dose Prediction: A Key Metric for Compound Progression in Drug Discovery. Molecular Pharmaceutics. 13(2). 609–620. 39 indexed citations
5.
Barlaam, Bernard, Sabina Cosulich, Bénédicte Delouvrié, et al.. (2015). Abstract 2830: Discovery of AZD8835, a potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of PIK3CA-dependent cancers. Cancer Research. 75(15_Supplement). 2830–2830.
6.
Savi, Chris De, David Waterson, Andrew R. Pape, et al.. (2013). Hydantoin based inhibitors of MMP13—Discovery of AZD6605. Bioorganic & Medicinal Chemistry Letters. 23(16). 4705–4712. 18 indexed citations
7.
8.
Dossetter, Alexander G., Jonathan Bowyer, Calum Cook, et al.. (2012). Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition. Bioorganic & Medicinal Chemistry Letters. 22(17). 5563–5568. 4 indexed citations
9.
Thompson, Richard A., Emre M. Isin, Yan Li, et al.. (2012). In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs. Chemical Research in Toxicology. 25(8). 1616–1632. 153 indexed citations
10.
Savi, Chris De, Andrew R. Pape, John G. Cumming, et al.. (2011). Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis. Bioorganic & Medicinal Chemistry Letters. 21(11). 3301–3306. 13 indexed citations
11.
Savi, Chris De, Andrew Morley, Galith Karoutchi, et al.. (2011). Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2. Bioorganic & Medicinal Chemistry Letters. 22(1). 271–277. 12 indexed citations
12.
Thompson, Richard A., Emre M. Isin, Yan Li, et al.. (2010). Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. Chemico-Biological Interactions. 192(1-2). 65–71. 69 indexed citations
13.
Morley, Andrew, Peter W. Kenny, Brenda Burton, et al.. (2009). 5-Aminopyrimidin-2-ylnitriles as Cathepsin K inhibitors. Bioorganic & Medicinal Chemistry Letters. 19(6). 1658–1661. 9 indexed citations
14.
Elliot, David J., Philip A. MacFaul, Andrew Morley, et al.. (2009). Novel inhibitors of the αvβ3 integrin—lead identification strategy. Bioorganic & Medicinal Chemistry Letters. 19(16). 4832–4835. 12 indexed citations
15.
Buttar, David, Martina Fitzek, Barry R. Hayter, et al.. (2008). Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable. Bioorganic & Medicinal Chemistry Letters. 18(16). 4723–4726. 6 indexed citations
16.
Roche, Philip J. R., et al.. (2008). Surface plasmon resonance sensor in the analysis of caffeine binding to CYP1A2 p450 monoxygenase in the presence and absence of NADPH. Sensors and Actuators B Chemical. 139(1). 97–103. 4 indexed citations
17.
Wang, He, Barbara Hanney, Alfred P. Spada, et al.. (2003). Potent quinoxaline-Based inhibitors of PDGF receptor tyrosine kinase activity. Part 2: the synthesis and biological activities of RPR127963 an orally bioavailable inhibitor. Bioorganic & Medicinal Chemistry Letters. 13(18). 3097–3100. 136 indexed citations
18.
Hulme, Christopher, K.J.M. Moriarty, Bruce E. Miller, et al.. (1998). The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I. Bioorganic & Medicinal Chemistry Letters. 8(14). 1867–1872. 15 indexed citations
19.
Hulme, Christopher, Rose Mathew, K.J.M. Moriarty, et al.. (1998). Orally active indole N-oxide PDE4 inhibitors. Bioorganic & Medicinal Chemistry Letters. 8(21). 3053–3058. 9 indexed citations
20.
Page, Ken. (1987). The future of cruise shipping. Tourism Management. 8(2). 166–168. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Raju Mohan Breakdown of academic impact, for papers by Robert B. McFadyen Breakdown of academic impact, for papers by Philip Lienau Breakdown of academic impact, for papers by Ted W. Johnson Breakdown of academic impact, for papers by Xiaoke Gu Breakdown of academic impact, for papers by Klaus Pors Breakdown of academic impact, for papers by Yasuhisa Kurogi Breakdown of academic impact, for papers by Karen A. Rossi Breakdown of academic impact, for papers by John J. Piwinski
Rankless by CCL
2026